Trevi Therapeutics Inc (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts

Trevi Therapeutics Inc (NASDAQ:TRVI) has received an average recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $16.75.

TRVI has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 7th. Svb Leerink initiated coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating and a $14.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of Trevi Therapeutics in a research note on Monday, June 3rd. They set a “buy” rating and a $20.00 price objective for the company. Leerink Swann initiated coverage on shares of Trevi Therapeutics in a research note on Monday, June 3rd. They set an “outperform” rating for the company. Finally, Needham & Company LLC initiated coverage on shares of Trevi Therapeutics in a research note on Monday, June 3rd. They set a “buy” rating and a $18.00 price objective for the company.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Trevi Therapeutics during the 2nd quarter worth approximately $26,000. Morgan Stanley acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $42,000. Northern Trust Corp acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $124,000. Vanguard Group Inc. acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $886,000. Finally, Omega Fund Management LLC acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $9,476,000. 79.48% of the stock is owned by institutional investors.

Shares of NASDAQ:TRVI traded down $0.07 on Friday, reaching $4.69. 1,246 shares of the company were exchanged, compared to its average volume of 10,754. Trevi Therapeutics has a 1-year low of $4.04 and a 1-year high of $10.62. The stock’s 50-day simple moving average is $5.08.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Read More: Do closed-end mutual funds pay dividends?

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit